3050 Science Park Road
Tel: (858) 824-0895
About Prometheus Biosciences
Prometheus Biosciences is a biotech company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic product candidates. While our initial focus was on IBD, we're now extending beyond gastrointestinal (GI) diseases to target other autoimmune diseases.
Prometheus360TM, our powerful precision medicine platform, combines proprietary technology with the world's most comprehensive collection of IBD patient data, to translate deep, complex data into precision therapeutic and diagnostic product candidates and continually identify new drug targets and unique disease biomarkers. We're headquartered in San Diego, CA.
The Power of Precision
49 articles with Prometheus Biosciences
Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease
Proceeds to accelerate clinical development of PRA023, a potential best in class TL1A antibody for IBD, and expansion of Promtheus' 360 platform
Prometheus Biosciences, Inc., ("Prometheus") a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of inflammatory bowel disease (IBD), announced today the appointment of Olivier Laurent, Ph.D. as Chief Technology Officer
Prometheus Biosciences, Inc., Inc. ("Prometheus"), a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced today that it has launched the Monitr™ COVID-19 Assistance Program (M.C.A.P.) to provide adult Crohn's disease (CD) patients with access to this valuable test.
Prometheus Biosciences, Inc., Enters Into Multi-Target Strategic Collaboration with Takeda to Develop Targeted Therapies for Inflammatory Bowel Disease
Agreement Leverages Prometheus Biosciences' Proprietary Bioinformatics Analysis Platform, Companion Diagnostics to Speed Development and Discovery
There has been recent coverage of 3D bioprinting and how it has the potential to create a brave new world of printed organs to be used in biopharma research and maybe someday to even be used in organ transplants.
Prometheus BioScience Inc. Provides Update On Hepastem NASH-Fibrosis Program With Late-Breaking Preclinical Data At 2016 American Association for Study of Liver Diseases Meeting
Prometheus BioScience Inc. Raises EUR 10 Million In A Series C-extension Financing To Advance Its Broad Product Pipeline In Liver Diseases
Prometheus BioScience Inc. and Rosetta Genomics Ltd. Announce License and Collaboration Agreement; Prometheus Gains U.S. Rights to Three microRNA-based Cancer Diagnostic Tests